{
    "body": "Inhibition of which enzyme is mechanism of action of alisertib?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24043741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22488249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22940834", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22772063", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23431463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22753585", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23037716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23153524", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22767670", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23180582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24501545", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22863010", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24101146", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23755375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23755370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22016509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23847761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23446853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22350019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23723712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24240108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22972611"
    ], 
    "ideal_answer": [
        "Alisertib (MLN8237) is selective Aurora kinase inhibitor that acts by interfering with spindle organization and chromosome alignment during mitosis. It has been tested in patients with gastric cancer, breast cancer, relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas, epithelial ovarian, fallopian tube, and primary peritoneal carcinoma."
    ], 
    "exact_answer": [
        "aurora kinase"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
    ], 
    "type": "factoid", 
    "id": "531dd4af267d7dd05300000d", 
    "snippets": [
        {
            "offsetInBeginSection": 1197, 
            "offsetInEndSection": 1363, 
            "text": "Inhibition of AURKA using an investigational small-molecule specific inhibitor, alisertib, decreased the HDM2 protein level and induced P53 transcriptional activity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240108", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 145, 
            "text": "Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101146", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 86, 
            "text": "Alisertib (MLN8237) is an investigational inhibitor of Aurora A kinase (AAK).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101146", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 408, 
            "offsetInEndSection": 680, 
            "text": "The spindle organization defects induced by alisertib have been used to develop a pharmacodynamic (PD) assay for Aurora A inhibition based on the percentage of mitotic cells with proper chromosomal alignment at the metaphase plate (% aligned spindles, abbreviated as AS). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101146", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 142, 
            "text": "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24043741", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 144, 
            "offsetInEndSection": 298, 
            "text": "We therefore designed a phase II study of alisertib, a selective AAK inhibitor, in patients with relapsed and refractory aggressive non-Hodgkin lymphomas.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24043741", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1017, 
            "offsetInEndSection": 1204, 
            "text": "In addition, we employed vMCF-7DRaf-1 cells that display high levels of endogenous cyclin-A and demonstrated that molecular targeting of Aurora-A by Alisertib reduces cyclin-A expression.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446853", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 219, 
            "text": "Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 159, 
            "offsetInEndSection": 278, 
            "text": "Alisertib (MLN8237) an investigational agent that inhibits Aurora A Ser/Thr kinase has shown activity in PTCL patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 709, 
            "offsetInEndSection": 951, 
            "text": "We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863010", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 204, 
            "text": "Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22772063", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 139, 
            "offsetInEndSection": 390, 
            "text": "This single-arm phase II study assessed single-agent efficacy and safety of the investigational AAK inhibitor MLN8237 (alisertib), in patients with platinum-refractory or -resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22772063", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 251, 
            "text": "This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral drug MLN8237 (alisertib), a small-molecule Aurora A kinase (AAK) inhibitor, in 87 adult patients with advanced solid tumors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22767670", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 107, 
            "offsetInEndSection": 306, 
            "text": "This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753585", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 148, 
            "text": "Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488249", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 113, 
            "offsetInEndSection": 244, 
            "text": "The investigational drug alisertib (MLN8237) is a novel Aurora A kinase inhibitor being studied in multiple Phase I and II studies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488249", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1215, 
            "offsetInEndSection": 1382, 
            "text": " Our collective data indicate that targeting Aurora A with alisertib represents a novel approach to increase the efficacy of ara-C that warrants further investigation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488249", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 147, 
            "text": "Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016509", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 266, 
            "offsetInEndSection": 413, 
            "text": "Here, we describe preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, incorporating these novel pharmacodynamic assays.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016509", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 435, 
            "offsetInEndSection": 587, 
            "text": "We investigated the selectivity of alisertib for AAK and ABK and studied the antitumor and antiproliferative activity of alisertib in vitro and in vivo.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016509", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 961, 
            "offsetInEndSection": 1193, 
            "text": "Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chromosomes in the HCT-116 xenograft model, a phenotype consistent with AAK inhibition.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016509", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1608, 
            "offsetInEndSection": 1662, 
            "text": "Alisertib is a selective and potent inhibitor of AAK. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016509", 
            "endSection": "abstract"
        }
    ]
}